SEC Form SC 13G/A filed by Adagene Inc. (Amendment)
$ADAG
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $7.00 | Outperform | Leerink Partners |
| 1/31/2025 | Overweight → Equal-Weight | Morgan Stanley | |
| 2/1/2022 | $27.00 → $15.00 | Overweight | Morgan Stanley |
Leerink Partners initiated coverage of Adagene with a rating of Outperform and set a new price target of $7.00
Morgan Stanley downgraded Adagene from Overweight to Equal-Weight
Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene's SAFEbody technology platform to generate a masked monoclonal antibody from the company's pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to receive development and commercialization milestones and royalties on net sales of products developed around this target. Peter Luo, Ph.D., Chief Executive Officer of Adagene said, "Our SAFEbody techn
SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year's CSCO Meeting, taking place September 10-14 in Jinan, China. Harnessing the Power of Masked CTLA-4 Blockade: Updated ADG126-P001 Phase 1b/2Results of ADG126 + Pembrolizumab in Advanced MSS CRC Presenter: Dr. Xu Ruihua, Professor and President of Sun Yat-sen University Cancer Center and Chairman of the Chinese Society of Clinical Oncology (CSCO)Date and Time: Thursday, September 11 at 14:45-15:
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad
6-K - Adagene Inc. (0001818838) (Filer)
6-K - Adagene Inc. (0001818838) (Filer)
SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a
SC 13G/A - Adagene Inc. (0001818838) (Subject)
SC 13D/A - Adagene Inc. (0001818838) (Subject)
SC 13G/A - Adagene Inc. (0001818838) (Subject)
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of